Exome Asset Management LLC 13F: Quarter-over-Quarter Portfolio Changes
Exome Asset Management LLC reported a disclosed portfolio value of approximately $162.1 million in its latest SEC Form 13F-HR filing for Q2 2026, down 4.6% quarter on quarter. Over the quarter, the fund initiated 15 new positions, bought more shares in 1 holding, trimmed 32 holdings, and exited 8 positions.
Exome Asset Management LLC's top buy was a new stake in Tg Therapeutics INC (TGTX) , equal to 5.6% of the disclosed portfolio. Its top sell was Elevance Health INC Formerly (ELV) . The fund exited the position completely after it had accounted for 2.5% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| TG THERAPEUTICS INC | TGTX | 5.6% | History → |
| ABIVAX SA | ABVX | 3.9% | History → |
| UNIQURE NV | QURE | 2.3% | Holders → |
| ASTRAZENECA PLC | AZN | 1.4% | Holders → |
| VIKING THERAPEUTICS INC | VKTX | 1.2% | Holders → |
| OCULAR THERAPEUTIX INC | OCUL | 1.1% | Holders → |
| EQUILLIUM INC | EQ | 1.1% | Holders → |
| ASCENDIS PHARMA A/S | ASND | 1.1% | Holders → |
| NEKTAR THERAPEUTICS | NKTR | 1.0% | Holders → |
| CLEARPOINT NEURO INC | CLPT | 0.9% | Holders → |
| CARIS LIFE SCIENCES INC | CAI | 0.9% | Holders → |
| GERON CORP | GERN | 0.5% | Holders → |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | 0.4% | Holders → |
| COMPASS THERAPEUTICS INC | CMPX | 0.4% | Holders → |
| REPLIMUNE GROUP, INC. | REPL | 0.3% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| MAZE THERAPEUTICS INC | MAZE | +0.6% | +29.6% | Holders → |
Top SellsQ2 2026
Showing the top 10 sells among 32 existing positions where the fund sold shares in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| RELAY THERAPEUTICS INC | RLAY | -1.1% | 82.9% | Holders → |
| BRIDGEBIO PHARMA INC | BBIO | -2.1% | 72.8% | Holders → |
| ENLIVEN THERAPEUTICS INC | ELVN | -1.9% | 54.5% | History → |
| INSMED INC | INSM | -1.7% | 47.9% | Holders → |
| AGIOS PHARMACEUTICALS INC | AGIO | -0.9% | 43.6% | Holders → |
| CYTOKINETICS INC | CYTK | -0.9% | 42.1% | History → |
| PRAXIS PRECISION MEDICINES I | PRAX | -3.0% | 40.2% | History → |
| ZENAS BIOPHARMA INC | ZBIO | -0.1% | 35.0% | Holders → |
| ADAGENE INC | ADAG | -0.4% | 33.7% | Holders → |
| ARBUTUS BIOPHARMA CORP | ABUS | -0.1% | 33.5% | Holders → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| ELEVANCE HEALTH INC FORMERLY | ELV | 2.5% |
| APELLIS PHARMACEUTICALS INC | APLS | 2.0% |
| AVALO THERAPEUTICS INC | AVTX | 1.4% |
| SOLENO THERAPEUTICS INC | SLNO | 1.2% |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | 0.7% |
| NEXTCURE INC | NXTC | 0.7% |
| PALISADE BIO INC | PALI | 0.6% |
| LIPOCINE INC NEW | LPCN | 0.3% |
Net Portfolio Value ChangeQ2 2026
- $0.2BPrior quarter
- $0.2BCurrent quarter
- $-0.0BNet delta
- -4.6%% change
Methodology & FAQ
How Exome Asset Management LLC Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Exome Asset Management LLC: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Exome Asset Management LLC buy in Q2 2026?
In Q2 2026, Exome Asset Management LLC initiated 15 new positions (TG THERAPEUTICS INC (TGTX), ABIVAX SA (ABVX), UNIQURE NV (QURE), ASTRAZENECA PLC (AZN), VIKING THERAPEUTICS INC (VKTX), OCULAR THERAPEUTIX INC (OCUL), EQUILLIUM INC (EQ), ASCENDIS PHARMA A/S (ASND), NEKTAR THERAPEUTICS (NKTR), CLEARPOINT NEURO INC (CLPT), CARIS LIFE SCIENCES INC (CAI), GERON CORP (GERN), BRIGHT MINDS BIOSCIENCES INC (DRUG), COMPASS THERAPEUTICS INC (CMPX), REPLIMUNE GROUP, INC. (REPL)); bought more shares of MAZE THERAPEUTICS INC (MAZE).
What stocks did Exome Asset Management LLC sell in Q2 2026?
In Q2 2026, Exome Asset Management LLC fully sold 8 positions (ELEVANCE HEALTH INC FORMERLY (ELV), APELLIS PHARMACEUTICALS INC (APLS), AVALO THERAPEUTICS INC (AVTX), SOLENO THERAPEUTICS INC (SLNO), 4D MOLECULAR THERAPEUTICS IN (FDMT), NEXTCURE INC (NXTC), PALISADE BIO INC (PALI), LIPOCINE INC NEW (LPCN)); reduced holdings in RELAY THERAPEUTICS INC (RLAY), BRIDGEBIO PHARMA INC (BBIO), ENLIVEN THERAPEUTICS INC (ELVN), INSMED INC (INSM), AGIOS PHARMACEUTICALS INC (AGIO) (the largest 5 of 32 reductions).
Which positions did Exome Asset Management LLC initiate in Q2 2026?
Exome Asset Management LLC established 15 new positions in Q2 2026: TG THERAPEUTICS INC (TGTX, 5.6%), ABIVAX SA (ABVX, 3.9%), UNIQURE NV (QURE, 2.3%), ASTRAZENECA PLC (AZN, 1.4%), VIKING THERAPEUTICS INC (VKTX, 1.2%), OCULAR THERAPEUTIX INC (OCUL, 1.1%), EQUILLIUM INC (EQ, 1.1%), ASCENDIS PHARMA A/S (ASND, 1.1%), NEKTAR THERAPEUTICS (NKTR, 1.0%), CLEARPOINT NEURO INC (CLPT, 0.9%), CARIS LIFE SCIENCES INC (CAI, 0.9%), GERON CORP (GERN, 0.5%), BRIGHT MINDS BIOSCIENCES INC (DRUG, 0.4%), COMPASS THERAPEUTICS INC (CMPX, 0.4%), REPLIMUNE GROUP, INC. (REPL, 0.3%).
Which existing positions saw the largest allocation increases for Exome Asset Management LLC in Q2 2026?
Of 1 existing position with share-count increases in Q2 2026, the largest were: MAZE THERAPEUTICS INC (MAZE, +0.6% weight, +29.6% shares).
Which positions did Exome Asset Management LLC fully exit in Q2 2026?
Exome Asset Management LLC fully exited 8 positions in Q2 2026: ELEVANCE HEALTH INC FORMERLY (ELV, last-reported weight 2.5%), APELLIS PHARMACEUTICALS INC (APLS, last-reported weight 2.0%), AVALO THERAPEUTICS INC (AVTX, last-reported weight 1.4%), SOLENO THERAPEUTICS INC (SLNO, last-reported weight 1.2%), 4D MOLECULAR THERAPEUTICS IN (FDMT, last-reported weight 0.7%), NEXTCURE INC (NXTC, last-reported weight 0.7%), PALISADE BIO INC (PALI, last-reported weight 0.6%), LIPOCINE INC NEW (LPCN, last-reported weight 0.3%).
Which existing positions saw the largest allocation reductions for Exome Asset Management LLC in Q2 2026?
Of 32 existing positions with share-count reductions in Q2 2026, the largest were: RELAY THERAPEUTICS INC (RLAY, -1.1% weight, -82.9% shares), BRIDGEBIO PHARMA INC (BBIO, -2.1% weight, -72.8% shares), ENLIVEN THERAPEUTICS INC (ELVN, -1.9% weight, -54.5% shares), INSMED INC (INSM, -1.7% weight, -47.9% shares), AGIOS PHARMACEUTICALS INC (AGIO, -0.9% weight, -43.6% shares), CYTOKINETICS INC (CYTK, -0.9% weight, -42.1% shares), PRAXIS PRECISION MEDICINES I (PRAX, -3.0% weight, -40.2% shares), ZENAS BIOPHARMA INC (ZBIO, -0.1% weight, -35.0% shares), ADAGENE INC (ADAG, -0.4% weight, -33.7% shares), ARBUTUS BIOPHARMA CORP (ABUS, -0.1% weight, -33.5% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.